Adjuvant Therapy of Melanoma with Interferon
Author Information
Author(s): Ascierto Paolo A, Kirkwood John M
Primary Institution: National Tumor Institute, Naples, Italy
Hypothesis
Does adjuvant interferon therapy improve survival rates in high-risk melanoma patients?
Conclusion
Adjuvant interferon significantly reduces the risk of relapse and mortality in high-risk melanoma patients, although the absolute improvement in survival is relatively small.
Supporting Evidence
- Interferon therapy showed a statistically significant benefit for overall survival.
- Patients with ulcerated primary melanoma had a greater benefit from interferon therapy.
- The absolute benefit of interferon therapy at 5 years was at least 3%.
Takeaway
This study shows that giving interferon to melanoma patients after surgery can help them live longer and avoid getting sick again, but the benefits are small.
Methodology
The study involved a meta-analysis of individual patient data from multiple trials assessing the effects of interferon on relapse-free and overall survival in melanoma patients.
Potential Biases
Potential biases may arise from the variability in treatment protocols and patient selection across different studies.
Limitations
The absolute benefit in survival is small, and the study highlights the need for further research to identify which patients benefit most from interferon therapy.
Participant Demographics
The study focused on high-risk melanoma patients, including those with stage III melanoma.
Statistical Information
P-Value
p = 0.008
Confidence Interval
CI 1–5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website